The market cap of Ainos, Inc. (OTCPINK: AIMD) grew to $204.83M on Tuesday after rising 51.58% on the day to close the session at $1.44. There were 49.56K shares of Ainos stock traded on the day, a volume which was greater than its average daily volume of 24.81K shares.  As a result of a rebranding, AIM’s stock price has increased.

What is AIMD’s rebranding strategy?

Ainos formerly known as Amarillo Biosciences, Inc. is a Texas corporation. As a diversified healthcare company, AIMD focuses on pharmaceutical and biotechnology research and development. To combat disease and enhance the body’s ability to heal, AIMD aims to introduce novel products that actively stimulate and rejuvenate the human body.

Currently, Ainos’ products include COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginitis, and helicobacter pylori test kits for point-of-care testing. There are offices of AIMD in Taiwan and the United States.

Ainos received the approval of FINRA (“the Financial Industry Regulatory Authority”) for the change from the Company’s previous name to “Ainos, Inc.” and “AIMD” as the Company’s new ticker symbol.

Since May 24, Ainos’ common stock has been trading under the symbol “AIMD”, and its new CUSIP number is 00902F105. As a result of these changes, AIMD announced in April 21, 2021 that a securities purchase transaction had been successfully closed with Cayman Islands corporation Ainos, Inc. (“Investor” or “Ainos KY”).

Moving forward:

Ainos (AIMD) has also signed a consulting agreement with Donohoe Advisory Associates LLC for help evaluating the listing requirements of national securities exchanges in the United States.